Tiziana’s Foralumab Meets Primary Endpoints in Phase 2a Multiple Sclerosis Trial
Tiziana’s Foralumab Meets Primary Endpoints in Phase 2a Multiple Sclerosis Trial Tiziana Life Sc
Story updates
07:01:04 PM UTC
SquawkNews
Trial met primary endpoint with a statistically significant reduction in microglial activation on TS
07:02:00 PM UTC
SquawkNews
Tiziana said its Phase 2a INFORM-MS trial met dual primary endpoints, including reduced microglial activation in the 50 μg arm. Fatigue scores fell 6.17 points and 7.18 points from baseline in the 50 μg and 100 μg arms, respectively; placebo fell 3.12 points.Material DetailsContext by AI AnalystThi…